Yeqian Feng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yeqian Feng has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
Chenzhe Feng
Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China
5 shared publicationsJunjie Wang
Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China
5 shared publications- Junjie Wang
Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China
5 shared publications Gouping Ding
4 shared publications- Gouping Ding
Department of Oncology, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, China
4 shared publications Haolin Chen
Department of General Surgery, Xiangya Hospital Central South University, Changsha, Hunan, China
4 shared publications
Latest Publications
- Open Access
- 26 October 2026
- Published by Springer Nature in Cancer Cell International
Artificial intelligence for predicting immune checkpoint inhibitor outcomes through multi-omics integration
- 26 October 2026
- Published by Springer Nature in Cancer Cell International
Open AccessArtificial intelligence for predicting immune checkpoint inhibitor outcomes through multi-omics integration
- Open Access
- 25 September 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1) , 916
Tumor cell membrane‑coated MOF‑199 nanoparticles co‑loaded with auranofin and celecoxib enhance single‑dose radiotherapy and anti‑PD‑L1 therapy in cervical cancer
- 25 September 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1) , 916
Open AccessTumor cell membrane‑coated MOF‑199 nanoparticles co‑loaded with auranofin and celecoxib enhance single‑dose radiotherapy and anti‑PD‑L1 therapy in cervical cancer
- Open Access
- 20 September 2026
- Published by Springer Nature in Molecular Cancer
- Vol. 25 (1) , 222
Immune-pressure redistribution in resistance to PD-1/PD-L1 blockade: mechanisms, biomarkers, and therapeutic design
PD-1/PD-L1 blockade can produce durable tumor control, yet primary, adaptive, and acquired resistance remain common. Existing accounts often catalogue resi
- 20 September 2026
- Published by Springer Nature in Molecular Cancer
- Vol. 25 (1) , 222
Open AccessImmune-pressure redistribution in resistance to PD-1/PD-L1 blockade: mechanisms, biomarkers, and therapeutic design
PD-1/PD-L1 blockade can produce durable tumor control, yet primary, adaptive, and acquired resistance remain common. Existing accounts often catalogue resi
- Open Access
- 16 September 2026
- Published by Elsevier in Materials Today Advances
- Vol. 32
Cancer-associated fibroblast–tumor organoid models of therapy resistance: mechanisms, materials, and translational potential
- 16 September 2026
- Published by Elsevier in Materials Today Advances
- Vol. 32
Open AccessCancer-associated fibroblast–tumor organoid models of therapy resistance: mechanisms, materials, and translational potential
- Open Access
- 28 July 2026
- Published by Elsevier in Translational Oncology
- Vol. 72, 102939
Single-cell and spatial transcriptomics uncover a THBS2⁺ CAF–KRT17⁺ malignant cell axis drives progression and immunotherapy resistance in pancreatic cancer
- 28 July 2026
- Published by Elsevier in Translational Oncology
- Vol. 72, 102939
Open AccessSingle-cell and spatial transcriptomics uncover a THBS2⁺ CAF–KRT17⁺ malignant cell axis drives progression and immunotherapy resistance in pancreatic cancer
- Open Access
- 7 June 2026
- Published by Wiley in Journal of Cellular Physiology
- Vol. 241 (6) , e70197
Immune Evasion in Ovarian Cancer Peritoneal Metastasis: Mechanisms and Biomarker‐Guided Therapeutic Matching
Ovarian cancer peritoneal metastasis remains a major cause of recurrence and death despite advances in cytoreductive surgery, platinum‐based chemotherapy, PARP inhibition, and immune checkpoint blockade. The limited activity of immunotherapy in this setting reflects layered immune resistance shaped by impaired antigen visibility, redundant inhibitory receptor networks, suppressive myeloid and regulatory circuits, and metabolic‐epigenetic constraints within ascites and multicellular spheroids. These compartment‐specific features distinguish peritoneal disease from anatomically confined tumors and help explain why systemic immune reinvigoration alone rarely produces durable benefit. Here, we synthesize current evidence on the mechanisms that govern immune escape in ovarian cancer peritoneal dissemination, with emphasis on antigen presentation defects, checkpoint‐driven T‐cell exhaustion, anti‐phagocytic signaling, soluble suppressive mediators, and metabolic remodeling of the ascites microenvironment. We further examine how DNA damage response states intersect with innate immune sensing and discuss the translational implications of homologous recombination deficiency for combination treatment design. Finally, we propose a biomarker‐guided framework that links antigen‐presentation competence, immune engagement, dominant suppressive axes, and ascites‐specific biology to rational therapeutic matching. This mechanism‐centered view supports more precise trial design and provides a roadmap for combination immunotherapy in advanced ovarian cancer.
- 7 June 2026
- Published by Wiley in Journal of Cellular Physiology
- Vol. 241 (6) , e70197
Open AccessImmune Evasion in Ovarian Cancer Peritoneal Metastasis: Mechanisms and Biomarker‐Guided Therapeutic Matching
Ovarian cancer peritoneal metastasis remains a major cause of recurrence and death despite advances in cytoreductive surgery, platinum‐based chemotherapy, PARP inhibition, and immune checkpoint blockade. The limited activity of immunotherapy in this setting reflects layered immune resistance shaped by impaired antigen visibility, redundant inhibitory receptor networks, suppressive myeloid and regulatory circuits, and metabolic‐epigenetic constraints within ascites and multicellular spheroids. These compartment‐specific features distinguish peritoneal disease from anatomically confined tumors and help explain why systemic immune reinvigoration alone rarely produces durable benefit. Here, we synthesize current evidence on the mechanisms that govern immune escape in ovarian cancer peritoneal dissemination, with emphasis on antigen presentation defects, checkpoint‐driven T‐cell exhaustion, anti‐phagocytic signaling, soluble suppressive mediators, and metabolic remodeling of the ascites microenvironment. We further examine how DNA damage response states intersect with innate immune sensing and discuss the translational implications of homologous recombination deficiency for combination treatment design. Finally, we propose a biomarker‐guided framework that links antigen‐presentation competence, immune engagement, dominant suppressive axes, and ascites‐specific biology to rational therapeutic matching. This mechanism‐centered view supports more precise trial design and provides a roadmap for combination immunotherapy in advanced ovarian cancer.
- Open Access
- 26 February 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Molecular and AI enabled prognostication in endometrial cancer a 2015 to 2024 bibliometric Atlas and critical review
Background Endometrial cancer (EC) is a leading gynecologic malignancy with increasing incidence and mortality, particularly in high-income countries. Traditional prognostic models based on clinicopathological features often fail to accurately stratify risk, especially in early-stage and low-risk cases. Methods A bibliometric analysis was performed on research articles published between 2015 and 2024, sourced from the Web of Science and Scopus databases. The analysis included publications on prognostic or risk models in EC and assessed key trends and themes within the field. Results The study reveals a significant shift toward molecular-based stratification, particularly with the Cancer Genome Atlas (TCGA) subtypes, and the incorporation of AI-driven models. Molecular markers, such as POLE-ultramutated and p53-abnormal tumors, alongside biomarkers like HE4 and L1CAM, offer improved prognostic accuracy. AI models, including radiomics and deep learning approaches, show promise in predicting disease recurrence and patient outcomes. Conclusion Advances in molecular classification and AI have improved EC prognostication. However, challenges remain in prospective validation and broader clinical implementation. Future research should focus on multi-omics integration and international collaboration to improve the accuracy and applicability of EC prognostic models. Graphical Abstract
- 26 February 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Open AccessMolecular and AI enabled prognostication in endometrial cancer a 2015 to 2024 bibliometric Atlas and critical review
Background Endometrial cancer (EC) is a leading gynecologic malignancy with increasing incidence and mortality, particularly in high-income countries. Traditional prognostic models based on clinicopathological features often fail to accurately stratify risk, especially in early-stage and low-risk cases. Methods A bibliometric analysis was performed on research articles published between 2015 and 2024, sourced from the Web of Science and Scopus databases. The analysis included publications on prognostic or risk models in EC and assessed key trends and themes within the field. Results The study reveals a significant shift toward molecular-based stratification, particularly with the Cancer Genome Atlas (TCGA) subtypes, and the incorporation of AI-driven models. Molecular markers, such as POLE-ultramutated and p53-abnormal tumors, alongside biomarkers like HE4 and L1CAM, offer improved prognostic accuracy. AI models, including radiomics and deep learning approaches, show promise in predicting disease recurrence and patient outcomes. Conclusion Advances in molecular classification and AI have improved EC prognostication. However, challenges remain in prospective validation and broader clinical implementation. Future research should focus on multi-omics integration and international collaboration to improve the accuracy and applicability of EC prognostic models. Graphical Abstract
- Open Access
- 23 February 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
Targeting redox metabolism and low-dose radiotherapy synergistically activate cGAS-STING pathway to improve NK cell therapy efficacy in hepatocellular carcinoma
Adoptive natural killer (NK) cell therapy (ANKCT) is a promising strategy for hepatocellular carcinoma (HCC); however, its efficacy is hampered by insuffic
- 23 February 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
Open AccessTargeting redox metabolism and low-dose radiotherapy synergistically activate cGAS-STING pathway to improve NK cell therapy efficacy in hepatocellular carcinoma
Adoptive natural killer (NK) cell therapy (ANKCT) is a promising strategy for hepatocellular carcinoma (HCC); however, its efficacy is hampered by insuffic
- Open Access
- 7 February 2026
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 45 (1)
Rewiring tumor cytokine networks to enhance immune checkpoint blockade: mechanisms, engineering, and clinical translation
Immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 and CTLA-4 can produce durable remissions in multiple solid tumors, yet primary and acquired resis
- 7 February 2026
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 45 (1)
Open AccessRewiring tumor cytokine networks to enhance immune checkpoint blockade: mechanisms, engineering, and clinical translation
Immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 and CTLA-4 can produce durable remissions in multiple solid tumors, yet primary and acquired resis
- Top Cited PapersOpen Access
- 23 January 2026
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1881 (2) , 189536
Precision cytokine modulation to overcome tumor microenvironment-driven resistance to immune checkpoint blockade
- 23 January 2026
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1881 (2) , 189536
Top Cited PapersOpen AccessPrecision cytokine modulation to overcome tumor microenvironment-driven resistance to immune checkpoint blockade